Bone Biologics
BBLG
4 hedge funds and large institutions have $1.83K invested in Bone Biologics in 2025 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
33% more funds holding
Funds holding: 3 → 4 (+1)
0.05% less ownership
Funds ownership: 0.13% → 0.08% (-0.05%)
91% less capital invested
Capital invested by funds: $20.8K → $1.83K (-$19K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$638 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$522 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
-$19.4K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
-$481 |
| 3 |
SS
SBI Securities
Tokyo,
Japan
|
-$1 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
TRCT
1
Tower Research Capital (TRC)
New York
| $806 | -$481 | -104 | -34% |
|
|
CS
2
Clear Street
New York
| $556 | +$638 | +138 | New |
|
|
3
UBS Group
Zurich,
Switzerland
| $455 | +$522 | +113 | New |
|
4
Bank of America
Charlotte,
North Carolina
| $16 | – | – | – |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| – | -$19.4K | -4,034 | Closed |
|
|
SS
6
SBI Securities
Tokyo,
Japan
| – | -$1 | – | – |
|
BBLG Hedge Fund Activity: Q2 2025 in Review
4 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Bone Biologics (BBLG) for Q2 2025, worth a combined $1.83K — down 91% from $20.8K a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new BBLG positions and 1 closed out — a net gain of 1 holder — while 0 added to existing stakes and 1 trimmed.
The largest buyer was Clear Street, opening a new position worth an estimated $638. The largest seller was Geode Capital Management, exiting entirely with an estimated $19.4K sold.
- 4 institutional investors held Bone Biologics (BBLG) as of Q2 2025, up from 3 in Q1 2025.
- Funds reported $1.83K of Bone Biologics stock for Q2 2025, down 91% quarter-over-quarter.
- 2 funds opened new Bone Biologics positions in Q2 2025 and 1 closed out, a net change of +1 holder.
- The largest Bone Biologics buyer in Q2 2025 was Clear Street, an estimated $638 added.
- The largest Bone Biologics seller in Q2 2025 was Geode Capital Management, an estimated $19.4K sold.
Based on aggregated 13F filings for Q2 2025.